Basit öğe kaydını göster

dc.contributor.authorKallen, Caleb B.
dc.contributor.authorEnsari, Tugba Altun
dc.contributor.authorKayisli, Umit A.
dc.contributor.authorSeli, Emre
dc.contributor.authorGuzel, Elif
dc.contributor.authorKaripcin, Fethiye Sinem
dc.date.accessioned2021-03-03T15:35:28Z
dc.date.available2021-03-03T15:35:28Z
dc.date.issued2011
dc.identifier.citationKaripcin F. S. , Ensari T. A. , Kayisli U. A. , Guzel E., Kallen C. B. , Seli E., "The mRNA-Binding Protein HuR is Regulated in the Menstrual Cycle and Repressed in Ectopic Endometrium", REPRODUCTIVE SCIENCES, cilt.18, sa.2, ss.145-155, 2011
dc.identifier.issn1933-7205
dc.identifier.othervv_1032021
dc.identifier.otherav_3fb91d12-4581-4d2a-ba2a-794e1d8802f3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/46623
dc.identifier.urihttps://doi.org/10.1177/1933719110382307
dc.description.abstractCytokines modulate turnover of the endometrium during the menstrual cycle and contribute to the pathogenesis of endometriosis. Gene expression for cytokines is often regulated by proteins that bind to adenosine- and uridine-rich elements (AREs) in their transcripts to stabilize or destabilize bound messenger RNAs (mRNAs). HuR/ELAVL1 is an RNA-binding protein that stabilizes ARE-containing mRNAs. We hypothesized that HuR might play a role in regulating cytokine expression during the menstrual cycle and in endometriosis and characterized the expression and regulation of HuR in eutopic and ectopic human endometrium. Tissue sections obtained from normal (n = 23) and ectopic (n = 16) endometrium were immunostained for HuR, and staining intensity was evaluated by HSCORE. Cultured stromal cells isolated from normal endometrium were treated with vehicle, estradiol (E2), progesterone (P), E2 + P, tumor necrosis factor-alpha (TNF-alpha), and interleukin 1 beta (IL-1 beta) for 24 hours, and HuR expression was determined by Western blot. HuR immunoreactivity was significantly lower in the early proliferative and late secretory phases (157.5 +/- 11.08 and 190.0 +/- 15.2, respectively), compared to the mid-late proliferative (270.0 +/- 8.0) and early-mid secretory phases (256.6 +/- 20.2; P < .01, analysis of variance [ANOVA]). Furthermore, HuR expression was significantly lower in ectopic endometrial cells compared to normal endometrium in mid-late proliferative and early-mid-secretory phases (P < .01). Estrogen, P, or cytokines did not alter HuR expression in cultured endometrial stromal cells. Increased HuR levels in the mid-menstrual phases are likely to contribute to reduced mid-cycle cytokine expression and enhanced cellular survival in eutopic endometrium. In ectopic endometrium, elevated cytokine levels associated with endometriosis likely reduce HuR expression.
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyokimya
dc.subjectCerrahi Tıp Bilimleri
dc.subjectKadın Hastalıkları ve Doğum
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectBiyoloji ve Biyokimya
dc.subjectÜREME BİYOLOJİSİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectKADIN HASTALIKLARI & DOĞUM
dc.titleThe mRNA-Binding Protein HuR is Regulated in the Menstrual Cycle and Repressed in Ectopic Endometrium
dc.typeMakale
dc.relation.journalREPRODUCTIVE SCIENCES
dc.contributor.departmentYale University , ,
dc.identifier.volume18
dc.identifier.issue2
dc.identifier.startpage145
dc.identifier.endpage155
dc.contributor.firstauthorID727369


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster